DB
PCRX icon

Dmitry Balyasny’s Pacira BioSciences PCRX Stock Holding History

Dmitry Balyasny’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,418
Closed -$2.41M – 3383
2026
Q1 		$2.41M Sell
106,418
-839,561
-89% -$18.7M ﹤0.01% 1703
2025
Q4 		$24.5M Sell
945,979
-939,092
-50% -$22.3M 0.03% 620
2025
Q3 		$48.6M Sell
1,885,071
-245,662
-12% -$6.03M 0.06% 374
2025
Q2 		$50.9M Buy
2,130,733
+565,288
+36% +$14.2M 0.08% 322
2025
Q1 		$38.9M Buy
1,565,445
+1,131,239
+261% +$27.1M 0.06% 373
2024
Q4 		$8.18M Buy
+434,206
New +$7.62M 0.01% 1047
2023
Q3 		– Sell
-644,738
Closed -$25.8M – 2610
2023
Q2 		$25.8M Buy
644,738
+615,047
+2,071% +$25.4M 0.06% 441
2023
Q1 		$1.21M Buy
+29,691
New +$1.18M ﹤0.01% 1672
2019
Q3 		– Sell
-188,752
Closed -$8.21M – 1478
2019
Q2 		$8.21M Buy
+188,752
New +$8.01M 0.05% 460
2019
Q1 		– Sell
-41,978
Closed -$1.81M – 1584
2018
Q4 		$1.81M Buy
41,978
+1,419
+3% +$66.2K 0.01% 744
2018
Q3 		$1.99M Sell
40,559
-14,358
-26% -$621K 0.01% 978
2018
Q2 		$1.76M Sell
54,917
-406,185
-88% -$14M 0.01% 970
2018
Q1 		$14.4M Buy
461,102
+83,389
+22% +$2.97M 0.06% 417
2017
Q4 		$17.2M Buy
377,713
+312,813
+482% +$12.4M 0.05% 455
2017
Q3 		$2.44M Sell
64,900
-137,309
-68% -$5.53M 0.01% 906
2017
Q2 		$9.64M Buy
202,209
+41,231
+26% +$1.91M 0.04% 547
2017
Q1 		$7.34M Sell
160,978
-14,281
-8% -$617K 0.03% 596
2016
Q4 		$5.66M Sell
175,259
-99,603
-36% -$3.32M 0.03% 656
2016
Q3 		$9.41M Buy
274,862
+229,732
+509% +$9M 0.05% 400
2016
Q2 		$1.52M Sell
45,130
-226,037
-83% -$11.1M 0.01% 711
2016
Q1 		$14.4M Buy
+271,167
New +$15.9M 0.09% 311
2015
Q4 		– Sell
-228,997
Closed -$9.41M – 1399
2015
Q3 		$9.41M Buy
+228,997
New +$14M 0.07% 356

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's PCRX Position: Q2 2026 in Review

Dmitry Balyasny sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 106,418 shares — an estimated $2.41M sold.

Dmitry Balyasny first reported a position in PCRX in Q3 2015 and held it in 22 quarters. The position peaked at $50.9M in Q2 2025. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Dmitry Balyasny reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 106,418 Pacira BioSciences shares in Q2 2026, an estimated $2.41M.
  • Dmitry Balyasny first reported a position in Pacira BioSciences in Q3 2015 and held it in 22 quarters.
  • Dmitry Balyasny's Pacira BioSciences position peaked at $50.9M in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.